Articles tagged with Cancer Patients
Researchers identified three long noncoding RNAs associated with worse outcomes in colorectal cancer patients, potentially serving as prognostic markers. The study's findings could enable doctors to separate high-risk patients from those at low risk of disease recurrence, leading to more effective treatment strategies.
Researchers developed a method to assess which patients with metastatic triple-negative breast cancer can benefit from immunotherapy. The tool uses predictive biomarkers and machine learning-based approaches to identify patients who are likely to respond to treatment.
A pilot study by NCCN Cancer Center demonstrates the usability of HERC in advancing equitable cancer care delivery, with all participating sites strongly agreeing on its applicability. The tool features 19 practice evaluation and change recommendations to address disparity and bias in care delivery.
Researchers identified a previously unknown form of lymph node-like structures in liver tumors that are associated with greater treatment response and lower recurrence rates. The structures, found in patients treated with immune checkpoint inhibitors, contain infection-fighting immune B cells and tumor-killing immune T cells.
Researchers have developed a technology called FarrSight-Twin that creates digital twins of real cancer patients to predict treatment response. The approach was tested on published clinical trials and showed accurate predictions in all simulated studies, with 75% response rate among patients receiving the predicted best treatment.
Non-Hispanic Black patients are more likely to receive inadequate care and experience poor survival outcomes due to delays in treatment initiation. Guideline-concordant care is crucial in improving survival rates among these patients.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
A new study published in JNCCN found that Medicaid expansion was associated with longer survival rates and reduced treatment delays for patients with HR-negative, HER2-positive breast cancer. The study used data from the National Cancer Database to review results for women diagnosed with this type of breast cancer between 2010 and 2018.
Researchers have developed a 'mini-protein' that targets cancer cells expressing Nectin-4, allowing for direct delivery of radiation to tumours. The treatment shows promise in targeting multiple types of cancers and has the potential to be safe for repeated administrations.
Researchers have discovered key mutations in certain cancer cells that render WRN inhibitors ineffective. The study found that prolonged exposure to these inhibitors can lead to the acquisition of mutations in the WRN gene, allowing cancer cells to survive and develop resistance.
The myeloMATCH program offers a portfolio of biomarker-driven treatment trials to accelerate precision medicine in myeloid malignancies. Patients can enroll in clinical trials throughout their cancer treatment journey, with test results returned quickly to assign them to the most appropriate trial.
The Colorectal Cancer Alliance's Project Cure CRC has awarded nearly $5 million in research grants to advance urgent science in colorectal cancer. Recent awardees are working on topics such as radioimmunotherapy, CRISPR technology, and the protein drug ProAgio to better understand and treat this disease.
Researchers found that physically fitter patients with metastatic lung cancer live longer and respond better to chemotherapy. The study identified biomarkers in blood plasma that can indicate which patients are most likely to respond to treatment.
A new study suggests that MRI can predict patient outcomes and the risk of tumor reccurrence or spread for patients with rectal cancer who have undergone chemotherapy and radiation. This information could help doctors determine the best course of treatment, including whether to spare patients from invasive surgery.
The UCLA Urology department has been awarded $6 million to continue the IMPACT program, providing comprehensive prostate cancer treatment for underinsured and uninsured Californians. The program has helped over 2,300 men receive treatment services since its inception.
Researchers reported a complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer patient with brain metastases. The patient achieved overall survival of 87 months and progression-free survival of 73 months after treatment sequencing.
Younger adults diagnosed with colorectal cancer have later-stage disease with more aggressive types of tumors. Obesity, family history, inflammatory bowel disease, and symptoms are strongly associated factors. These findings highlight disparities in colon cancer incidence among younger adults, particularly non-Hispanic Black patients.
A study analyzing Reddit posts reveals that breast cancer patients struggle with unmet emotional and financial concerns during treatment and long after. The research highlights the importance of providing adequate support and education to address these concerns.
Researchers at Weill Cornell Medicine have discovered a biomarker that can predict which patients with liver cancer are likely to benefit from immunotherapy. The study found that high levels of the immune-suppressing protein NBR1 may identify patients who will not respond to treatment, while lowering NBR1 levels may help shrink tumors.
Researchers developed an AI model that uses machine learning and combination theory to predict suspicious skin lesions. The new C4C Risk Score has an accuracy of 69% and significantly outperformed existing methods, including 7PCL and Williams score.
The two-year progression-free survival rate was 92% on the N-AVD arm compared to 83% on the BV-AVD arm, with fewer side effects and lower mortality rates. The study's results support the use of nivolumab-AVD as a standard treatment for stage 3-4 classic Hodgkin lymphoma.
A groundbreaking study has demonstrated the clinical success of a new nanoparticle-based, laser-guided therapy for prostate cancer treatment. The therapy successfully eliminated cancerous cells in 73% of patients after 12 months while preserving key functions and side effects.
Children who survived childhood brain cancer are more likely to struggle academically, with a greater chance of being held back and performing poorly on state testing. The study's findings highlight the need for better support and resources to help these students succeed.
A study by Johns Hopkins Medicine found distinct immune 'signatures' in patients who developed adverse events while taking immunotherapy. These signatures, including increases in white blood cells known as Th2 and Th17, predict the development of immune-related adverse events and may be targeted for treatment.
Researchers found that certain factors increased the risk of death after sepsis, including advanced age, dementia, heart disease, cancer, and previous hospitalizations. A total of 50.6% of patients with sepsis died within two years, highlighting the need for closer monitoring and follow-up care.
A new study has found that using a higher dosage of radioembolisation treatment with yttrium-90 microspheres can improve overall survival outcomes for liver cancer patients. Patients who received this elevated dose had significantly better results, with some experiencing prolonged survival and even curative treatments.
Aerobic physical activity was associated with modest short-term and long-term reductions of depression among adults with cancer. The study suggests that aerobic exercise may be an effective strategy for managing depression in cancer patients.
A recent analysis reveals that the Dependent Coverage Expansion (DCE) provision of the Affordable Care Act has improved the survival rates and reduced the death rates of young adults diagnosed with cancer. The study found a significant improvement in both cancer survival and death rate trends after ACA implementation, particularly for ...
Researchers have used AI to analyze digital images of pathology slides and identified risk factors for aggressive brain tumors that differ between men and women. These findings could lead to more individualized care and improved treatment outcomes for glioblastoma patients.
A non-invasive blood test measuring circulating tumor cells can predict treatment response, disease progression, and overall survival in men with metastatic prostate cancer. Patients with more CTCs had shorter median survival lengths and a greater risk of death.
Recent clinical trials of neoadjuvant therapy before radical prostatectomy, such as the ACDC-RP trial, have struggled to show significant survival benefits. Researchers recommend maximal androgen blockade with an androgen receptor pathway inhibitor as the 'backbone' of neoadjuvant therapy trials.
A new CAR-T cell therapy targeting CD7 on leukaemia cells has shown promising results in treating T-ALL patients who have exhausted all standard treatment options. The therapy achieved complete remission in 16 out of 17 patients, with some remaining in remission for over five years.
A study published in Blood reported high response rates of 89% and complete responses of 70% among patients with relapsed or refractory multiple myeloma who received cilta-cel infusions. The results were comparable to those seen in clinical trials, suggesting the therapy's effectiveness in real-world settings.
A new study published in JAMA Network Open found that racial and ethnic minorities are more likely to have claims for free preventive care denied by insurance plans, leading to unexpected bills or lack of access. Healthcare providers also charge disadvantaged groups a higher amount for preventive services.
A new non-invasive imaging technique has been shown to accurately detect clear-cell renal cell carcinoma, the most common form of kidney cancer. The technique uses a monoclonal antibody drug that targets the protein CA9, highly expressed in up to 95% of clear cell kidney cancers.
A randomized phase 3 trial found that extended lymph node removal in bladder cancer surgery does not improve disease-free or overall survival but increases the risk of complications and death. The standard bilateral pelvic lymphadenectomy is considered a sufficient approach for these patients.
Researchers discovered TERT gene activation as a key factor in determining the clinical course of pulmonary carcinoid tumours, with aggressive growth linked to telomerase activation. The study aims to improve treatment planning and targeted therapeutic strategies for cancer types.
Two UCF cancer researchers, Alicja Copik and Debbie Altomare, have received $100,000 grants from the Florida Breast Cancer Foundation to develop new treatments for breast cancer. They focus on enhancing natural killer cells to fight cancer and harnessing the body's immune system to create new therapies.
The American College of Chest Physicians has released a new clinical guideline on endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) specimen processing and handling to standardize the process. The guidelines aim to improve diagnostic yield and specimen preservation for downstream ancillary testing.
A retrospective analysis of over 2,600 patients found that Black children were more likely to suffer severe graft-versus-host disease but overall survival rates improved across all racial groups. The study suggests that cord blood transplants are a vital lifeline for many patients and improve care for those without a matched donor.
A randomized trial halted after patients in the control arm reached a record high two-year progression-free survival rate of 98%. Deintensified treatments involving lower radiation dose and immunotherapy did not perform as well as standard chemoradiation.
A multi-center phase III trial found photon- and proton-based radiation therapies to be similarly safe and effective in treating low- and intermediate-risk prostate cancer. Patients treated with either IMRT or proton therapy reported no significant differences in quality of life, tumor control, or progression-free survival.
A survey found that spiritual beliefs and distrust of clinical research contribute to Black patients' hesitation to enroll in cancer trials. Despite trusting their medical teams, some patients express concerns about the purpose of research and its potential impact on their health and community.
A new study found that the IOTA ADNEX ultrasound model can detect up to 96% of ovarian cancers in postmenopausal women, outperforming the current standard test. The research team recommends replacing the risk of malignancy (RMI1) test with the IOTA ADNEX model.
A new study found that hypofractionation does not increase complications for patients with breast cancer who undergo mastectomy and plan breast reconstruction. The trial enrolled 898 patients and showed that reducing treatment time by nearly half is safe and effective, saving patients time and money.
A study published in Blood Advances found that CAR-T therapy can be administered safely and effectively on an outpatient basis in community hospitals, mitigating barriers to access. The treatment showed high efficacy rates, with 80% of patients experiencing an objective response and 54% achieving a complete response.
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.
A pooled analysis of three large, phase III clinical trials found that more than 40% of brain metastases patients can fully reverse cognitive losses with conformal radiation techniques. Recovery was more likely for those treated with highly targeted radiation compared to standard whole-brain treatment.
A phase II clinical trial found that radiopharmaceuticals, specifically 177Lu-Dotatate, can extend progression-free survival for patients with refractory meningioma by nearly 80% after six months. The therapy offers a safe and effective treatment option for those with aggressive tumor growth.
Early-stage HR+ breast cancer survivors experience weight gain, particularly those with healthy BMI or overweight at diagnosis. Black women have higher rates of obesity and related comorbidities compared to White women, leading to a 40% higher breast cancer mortality rate.
A recent study reveals that pharmaceutical industry sponsors dominate US cancer research, with a substantial increase in industry-sponsored clinical trials over the past decade. Federally funded studies have been underinvested and have missed opportunities for scientific advancements.
UCLA investigators presented data on chemoradiotherapy in rectal cancer, MRI-guided radiotherapy for prostate cancer, and symptom self-reporting during treatment. Researchers developed a predictive model to identify patients most likely to respond to chemoradiotherapy in rectal cancer.
A new online tool has been shown to reduce decisional conflict in women with breast cancer undergoing mastectomy, supporting informed decisions on immediate breast reconstruction. The study found that patients who used the tool felt better prepared for decision-making and had a lower rate of clinically significant decisional conflict.
Researchers have developed a new method to detect melanoma using tumour-specific antibodies, which can accurately identify stage I and II melanoma patients. The study found that these antibodies showed high sensitivity and specificity in detecting melanoma, with an AUC value of up to 0.981.
A new study has found that baseline testosterone, age, and duration of ADT are key predictors of testosterone recovery. The researchers developed a nomogram to estimate recovery times based on patient-specific characteristics, providing valuable insights for improving patient outcomes.
Dr. Roger Lo has been awarded a $2 million NIH grant to investigate ways to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors. The team aims to target genetic instability and immune evasion to stabilize the melanoma genome and make it more vulnerable to immune attacks.
A new risk prediction model identifies patients with advanced cancer who are at highest risk for unplanned emergency room visits and hospital stays. The model, developed by researchers from the SWOG Cancer Research Network, considers factors such as performance status, comorbidities, and cancer type.
The Affordable Care Act has led to increased guideline-concordant care for non-white patients, rural residents, and those from the most deprived neighborhoods in Pennsylvania. This improvement is associated with better cancer outcomes, including survival rates.
A study found that Black women with breast cancer are more likely to experience vaginal dryness, reduced libido, and painful intercourse, leading to lower mental quality of life. These symptoms were associated with decreased adherence to treatment in these patients.
A nonrandomized clinical trial found that wearable devices can increase moderate-to-vigorous physical activity and reduce dyspnea at 6 months post-lung cancer surgery. This suggests a promising role for wearable devices in personalizing perioperative rehabilitation strategies.